EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Efficacy Analysis and Prognostic Impact of Sivelestat Sodium in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome

Xiao Che, Wei Hu, Ziying Zhang, Lexiao Wang, Zhe Xu, Fusheng Wang

Pharmaceuticals · 12.03.2024 · 17 (3) · 368

DOI: 10.3390/ph17030368 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 12.03.2024. Verfasst von Xiao Che und 5 weiteren Autor:innen. Beteiligte Einrichtung: Senior Department of Infectious Disease, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fu-sheng Wang, Zhe Xu, The National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to evaluate the efficacy of sivelestat sodium on mortality, oxygenation index, and serum markers in patients with acute respiratory distress syndrome (ARDS) associated with Coronavirus Disease 2019 (COVID-19).

Methods

A retrospective analysis was conducted on adult inpatients admitted to the Intensive Care Unit (ICU). The study compared clinical characteristics, laboratory indices, and mortality rates between patients treated with and without sivelestat sodium. Cox regression analysis was employed to assess the effect of sivelestat sodium on the risk of death, oxygenation index, and improvement of serum markers in patients with COVID-19-associated ARDS.

Results

A total of 110 patients with COVID-19-associated ARDS were included, with 45 patients in the sivelestat group and 65 patients in the control group. The overall patient mortality rate was 69.1%, with 62.2% in the sivelestat group and 73.8% in the control group. After five days of treatment, the median change from baseline in the oxygenation index was 21 mmHg in the medicated group and −31 mmHg in the control group (p < 0.05). Analysis of the oxygenation index as a clinical endpoint event showed a significantly higher rate of improvement in the sivelestat group compared to the control group (57.8% vs. 38.5%, p < 0.05), and the odds of raising the oxygenation index after treatment were 2.05 times higher in the sivelestat group than in the control group (HR = 2.05, 95%CI: 1.02–4.15, p < 0.05). Among patients with a baseline oxygenation index < 200 mmHg, patients in the sivelestat group had an 86% lower risk of death compared to the control group (HR = 0.14, 95%CI: 0.02–0.81, p < 0.05).

Conclusions

Sivelestat sodium demonstrated a significant improvement in the oxygenation index of patients with COVID-19-associated ARDS and was found to considerably reduce the risk of death in patients with a baseline oxygenation index of

Schlagwörter

Stichwörter der Autor:innen

ARDSCOVID-19mortality ratesivelestat sodium

Autor:innen und Institutionen

  • Senior Department of Infectious Disease, The Fifth Medical Center of PLA General Hospital, Beijing 100039, China.

Förderung

  • Fu-sheng Wang, Zhe Xu
  • The National Key Research and Development Program of China

Zitieren

APA

Che, X., Hu, W., Zhang, Z., Wang, L., Xu, Z., & Wang, F. (2024). Efficacy Analysis and Prognostic Impact of Sivelestat Sodium in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome. Pharmaceuticals, 17(3), 368. https://doi.org/10.3390/ph17030368

Vancouver

Che X, Hu W, Zhang Z, Wang L, Xu Z, Wang F. Efficacy Analysis and Prognostic Impact of Sivelestat Sodium in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome. Pharmaceuticals. 2024;17(3):368. doi:10.3390/ph17030368

BibTeX
@article{Che2024,
  author = {Che, Xiao and Hu, Wei and Zhang, Ziying and Wang, Lexiao and Xu, Zhe and Wang, Fusheng},
  title = {Efficacy Analysis and Prognostic Impact of Sivelestat Sodium in Coronavirus Disease 2019-Related Acute Respiratory Distress Syndrome},
  journal = {Pharmaceuticals},
  year = {2024},
  volume = {17},
  number = {3},
  pages = {368},
  doi = {10.3390/ph17030368}
}
Kostenlos starten →